{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:56Z","timestamp":1794315416585,"version":"4.9.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Uveitis is a major manifestation of Beh\u00e7et disease (BD) and potentially has a high morbidity. This article reviews recently published data on BD uveitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A set of classification criteria and a diagnostic algorithm have been developed for BD uveitis. Recent reports have confirmed male predominance and posterior segment inflammation in the majority of BD uveitis patients. A high uveitis attack severity score, fluorescein angiographic leakage at the posterior pole, and disruption of outer retinal layers on optical coherence tomography (OCT) predict poor visual outcome. OCT-angiography studies have suggested subclinical changes of retinal capillaries in patients with or without ocular involvement. In a randomized controlled trial, interferon-\u03b1 was superior to cyclosporine. Favorable outcomes were reported with earlier initiation, optimization, and withdrawal of infliximab after remission. Adalimumab as first-line was superior to conventional therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Classification criteria will be used to select a homogeneous group of patients for research and the diagnostic algorithm may help ophthalmologists predict the probability of BD uveitis based on ocular findings. Fluorescein angiography and OCT are the routine imaging modalities. Clinical relevance of OCT-angiography is unclear. Interferon-\u03b1, infliximab, and adalimumab have proven superior efficacy compared to conventional therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000911","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T16:01:45Z","timestamp":1666108905000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Uveitis in Beh\u00e7et disease - an update"],"prefix":"10.1097","volume":"35","author":[{"given":"Ilknur","family":"Tugal-Tutkun","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University"},{"name":"Bayrampasa Eye Hospital, Eye Protection Foundation, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"R1-20250526","first-page":"1152","article-title":"\u00dcber rezidivierende, apht\u00f6se, durch ein Virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien","volume":"105","author":"Beh\u00e7et","year":"1937","journal-title":"Dermatologische Wochenschr"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Beh\u00e7et's syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-020-02406-6","article-title":"Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Beh\u00e7et's disease in Japan","volume":"23","author":"Soejima","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","article-title":"Cluster analysis of phenotypes of patients with Beh\u00e7et's syndrome: a large cohort study from a referral center in China","volume":"23","author":"Zou","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.reuma.2020.04.007","article-title":"Beh\u00e7et's disease phenotypes and clinical outcomes: a cohort study in Egyptian patients","volume":"17","author":"Attia","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Beh\u00e7et disease uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R7-20250526","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ajo.2021.07.036","article-title":"Comment on \u201cClassification Criteria for Beh\u00e7et Disease Uveitis\u201d","volume":"235","author":"Tugal-Tutkun","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ajo.2021.10.020","article-title":"Standardization of Uveitis Nomenclature Sun Working Group. Reply to Comment on: classification criteria for Beh\u00e7et disease uveitis","volume":"235","author":"Okada","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"(Suppl 132)","key":"R10-20250526","doi-asserted-by":"crossref","first-page":"43","DOI":"10.55563\/clinexprheumatol\/0hia54","article-title":"Initial visit symptoms in probable Beh\u00e7et's syndrome is predictive of ISG criteria fulfillment in Beh\u00e7et's syndrome: data from New York and Amsterdam cohorts","volume":"39","author":"Kerstens","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1093\/rheumatology\/keac018","article-title":"Evaluation of sensitivity and specificity of diagnostic criteria for Beh\u00e7et's disease in the absence of a gold standard","volume":"61","author":"Zhong","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/09273948.2020.1736310","article-title":"An algorithm for the diagnosis of Beh\u00e7et disease uveitis in adults","volume":"29","author":"Tugal-Tutkun","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11739-019-02248-4","article-title":"Beh\u00e7et's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics","volume":"15","author":"Sota","year":"2020","journal-title":"Intern Emerg Med"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/03009742.2021.1904622","article-title":"Patient characteristics in Beh\u00e7et's syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases","volume":"51","author":"Torgutalp","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4274\/tjo.galenos.2020.28485","article-title":"Comparison of sociodemographic features between Beh\u00e7et uveitis and other noninfectious uveitis","volume":"51","author":"Yal\u00e7inda\u011f","year":"2021","journal-title":"Turk J Ophthalmol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.2147\/OPTH.S287298","article-title":"Pattern of uveitis associated with Beh\u00e7et's disease in an Egyptian cohort","volume":"14","author":"Abd El Latif","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-020-00172-1","article-title":"Diagnosis of Beh\u00e7et's disease: clinical characteristics, diagnostic criteria, and differential diagnoses","volume":"5","author":"Kiafar","year":"2021","journal-title":"BMC Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41433-021-01585-z","article-title":"Incidence of ophthalmic involvement in Beh\u00e7et's disease in the United Kingdom: a British Ophthalmic Surveillance Unit (BOSU) study","volume":"36","author":"Parvizi","year":"2022","journal-title":"Eye (Lond)"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5152\/eurjrheum.2020.21199","article-title":"Clinical manifestations of Beh\u00e7et's syndrome: a single-center cohort of 777 patients","volume":"8","author":"G\u00fcrb\u00fcz","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-022-02782-1","article-title":"Clinical heterogeneity of ocular Beh\u00e7et's syndrome versus intestinal Beh\u00e7et's syndrome: a cross-sectional study from Shanghai Beh\u00e7et's syndrome database","volume":"24","author":"Hou","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/03009742.2021.1885735","article-title":"Clinical phenotypes of Beh\u00e7et's syndrome in a large cohort of Italian patients: focus on gender differences","volume":"50","author":"Leccese","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"R23-20250526","first-page":"roac044","article-title":"Cluster analysis of pediatric Beh\u00e7et's disease: data from the Pediatric Rheumatology Academy (PeRA)-Research Group (RG)","author":"Demir","year":"2022","journal-title":"Mod Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10067-021-05896-0","article-title":"Juvenile Beh\u00e7et's disease: a tertiary center experience","volume":"41","author":"Ekici Tekin","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s11739-021-02725-9","article-title":"Clinical profile and evolution of patients with juvenile-onset Beh\u00e7et's syndrome over a 25-year period: insights from the AIDA network","volume":"16","author":"Sota","year":"2021","journal-title":"Intern Emerg Med"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/25785826.2020.1800244","article-title":"Evaluation of disease activity in uveoretinitis associated with Beh\u00e7et's disease","volume":"44","author":"Keino","year":"2021","journal-title":"Immunol Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for diagnostics of the year: multimodal imaging in Beh\u00e7et uveitis","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R28-20250526","first-page":"1","article-title":"Ultra-widefield fluorescein angiography to monitor therapeutic response to adalimumab in Behcet's uveitis","author":"Kim","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-021-00318-4","article-title":"Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease","volume":"7","author":"Keorochana","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00417-020-04958-4","article-title":"Macular structural changes and factors affecting final visual acuity in patients with Beh\u00e7et uveitis","volume":"259","author":"Yal\u00e7inda\u011f","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3928\/23258160-20210330-06","article-title":"Macular cone abnormalities in Beh\u00e7et's Disease detected by adaptive optics scanning light ophthalmoscope","volume":"52","author":"Kadomoto","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"20037","DOI":"10.1038\/s41598-021-99485-5","article-title":"Peripapillary optical coherence tomography as an alternative to fluorescein angiography for monitoring Behcet's retinal vasculitis","volume":"11","author":"Zarei","year":"2021","journal-title":"Sci Rep"},{"key":"R33-20250526","first-page":"1","article-title":"Macrophage-like cells characterized by en face optical coherence tomography was associated with fluorescein vascular leakage in Beh\u00e7et's uveitis","author":"Zeng","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-018-0117-z","article-title":"Comparison between optical coherence tomography angiography and fluorescein angiography findings in retinal vasculitis","volume":"4","author":"Abucham-Neto","year":"2018","journal-title":"Int J Retina Vitreous"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"911990","DOI":"10.3389\/fmed.2022.911990","article-title":"Retinal and choroidal microvascular alterations in Behcet's disease without ocular manifestations: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41598-021-04730-6","article-title":"Retinal microvasculature features in patients with Behcet's disease: a systematic review and meta-analysis","volume":"12","author":"Ji","year":"2022","journal-title":"Sci Rep"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1007\/s10792-021-01968-x","article-title":"Postremission retinal microvascular and choroidal thickness changes in eyes with Behfx1et's disease posterior uveitis: an OCTA longitudinal study","volume":"41","author":"Wassef","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"727151","DOI":"10.3389\/fmed.2021.727151","article-title":"Vascular abnormalities in peripapillary and macular regions of Behcet's uveitis patients evaluated by optical coherence tomography angiography","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","article-title":"A treat-to-target approach is needed for Beh\u00e7et's syndrome","volume":"34","author":"Hatemi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-021-01011-z","article-title":"Advances in the treatment of Behcet's disease","volume":"23","author":"Alibaz-Oner","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"699903","DOI":"10.3389\/fphar.2021.699903","article-title":"Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-a when combined with glucocorticoid in the treatment of refractory Beh\u00e7et's uveitis: a randomized controlled prospective study","volume":"12","author":"Qian","year":"2021","journal-title":"Front Pharmacol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","article-title":"Effectiveness of infliximab and interferon alpha-2a for the treatment of Beh\u00e7et'suveitis: customizing therapy according to the clinical features","volume":"30","author":"De Simone","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"912906","DOI":"10.3389\/fphar.2022.912906","article-title":"Antitumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with Beh\u00e7et's disease: a systematic review of controlled trials","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"813","DOI":"10.18240\/ijo.2022.05.19","article-title":"Effects of anti-TNF biologic drugs on uveitis severity in Beh\u00e7et patients: systematic review and meta-analysis","volume":"15","author":"Abolhasani","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R45-20250526","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-022-02495-z","article-title":"Long-term outcomes of infliximab in patients with Beh\u00e7et's disease-associated uveitis","author":"Yamana","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bjophthalmol-2020-316892","article-title":"Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Beh\u00e7et's disease","volume":"105","author":"Keino","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1774907","article-title":"Clinical follow-up of patients with Beh\u00e7et uveitis after discontinuation of infliximab therapy","volume":"30","author":"K\u00f6se","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10384-021-00872-2","article-title":"An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Beh\u00e7et's disease in long-term remission","volume":"65","author":"Ida","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"609148","DOI":"10.3389\/fphar.2021.609148","article-title":"The efficacy of adalimumab as an initial treatment in patients with Beh\u00e7et's retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R50-20250526","first-page":"1","article-title":"Efficacy of biosimilar adalimumab in the treatment of Beh\u00e7et's uveitis","author":"Soheilian","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40123-021-00387-6","article-title":"Role of Adalimumab biosimilar in the treatment of nonanterior uveitis associated with Beh\u00e7et's syndrome","volume":"10","author":"Sota","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3899\/jrheum.200300","article-title":"Long-term follow-up and optimization of infliximab in refractory uveitis due to Beh\u00e7et disease: national study of 103 white patients","volume":"48","author":"Mart\u00edn-Varillas","year":"2021","journal-title":"J Rheumatol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/rheumatology\/keab944","article-title":"Emergence of new manifestations during infliximab treatment in Beh\u00e7et's syndrome","volume":"61","author":"Tukek","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","article-title":"Monthly intravitreal infliximab in Beh\u00e7et's disease active posterior uveitis: a long-term safety study","volume":"41","author":"Refaat","year":"2021","journal-title":"Retina"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet's disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"(Suppl 132)","key":"R57-20250526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Beh\u00e7et's disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R58-20250526","first-page":"1600","article-title":"Antiinterleukin 6 receptor antibody tocilizumab was not satisfactory for refractory Beh\u00e7et's uveitis in three consecutive patients","volume":"40","author":"Zhao","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R59-20250526","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome\u2019","author":"Zou","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:22Z","timestamp":1748294242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000911","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}